Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FAVIDOSE: High Dose Favipiravir in Healthy Volunteers
NCT06024421Phase 1Recruiting
- Sponsor
- Inserm
- Start
- May 2024
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of favipiravir in viral infection (6 arms), sponsored by Inserm. Primary endpoint: Tolerance at Month 6. Started May 2024; status: recruiting.
02
Drugs
favipiravir
03
Conditions
viral infection
Beyond the preview
Go deeper on NCT06024421.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06024421.